97 related articles for article (PubMed ID: 25912472)
1. Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report.
Bonnet C; Sibon I
Rev Neurol (Paris); 2015 Sep; 171(8-9):677-9. PubMed ID: 25912472
[No Abstract] [Full Text] [Related]
2. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
3. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
5. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
[No Abstract] [Full Text] [Related]
6. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
7. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
8. Cardiovascular toxicity of new agents.
Maitland ML
Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788
[No Abstract] [Full Text] [Related]
9. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
[No Abstract] [Full Text] [Related]
10. [Dysthyroidism with anti-VEGF treatment, a class effect? about one case report].
Khouri C; Jean Bart E; Logerot S; Decker-Bellaton A; Bontemps H; Mallaret M
Therapie; 2014; 69(6):521-4. PubMed ID: 25293486
[TBL] [Abstract][Full Text] [Related]
11. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib-induced acute psychosis: case report.
Kunene V; Porfiri E
Clin Genitourin Cancer; 2011 Sep; 9(1):70-2. PubMed ID: 21729680
[No Abstract] [Full Text] [Related]
13. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
[No Abstract] [Full Text] [Related]
14. Targeted therapies for kidney cancer in urologic practice.
Haas NB; Uzzo RG
Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Rini BI
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
[TBL] [Abstract][Full Text] [Related]
16. [Intravenous fibrinolysis in a 14-year-old male with cerebral infarction due to dissection of the internal carotid artery].
González-Suárez I; Fernández-Travieso J; Fuentes B; Ruiz-Ares G; Martínez-Martínez M; Díez-Tejedor E
Rev Neurol; 2012 Aug; 55(3):189-90. PubMed ID: 22825979
[No Abstract] [Full Text] [Related]
17. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
18. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
Rolleman EJ; Weening J; Betjes MG
Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
[No Abstract] [Full Text] [Related]
19. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
20. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
